With two innovative cancer treatment candidates that seek to block the “cloaking signal” used by cancer cells to trick the immune system into not attacking them, the small biotech highlighted in today’s article could present a massive opportunity. Shares of the company are up 1,500% since the beginning of the year – and the author believes that the stock’s surge may just be getting started. For more, CLICK HERE.